AprilBio Co.,Ltd.

KOSDAQ:A397030 Stock Report

Market Cap: ₩359.4b

AprilBioLtd Valuation

Is A397030 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A397030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A397030's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A397030's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A397030?

Key metric: As A397030 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A397030. This is calculated by dividing A397030's market cap by their current book value.
What is A397030's PB Ratio?
PB Ration/a
Book₩0
Market Cap₩359.44b

Price to Book Ratio vs Peers

How does A397030's PB Ratio compare to its peers?

The above table shows the PB ratio for A397030 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average10.2x
A199800 ToolGen
18.2xn/a₩365.3b
A347850 D&D Pharmatech
5.5xn/a₩410.1b
A226950 OliX Pharmaceuticals
14.2xn/a₩363.7b
A215600 SillaJen
3xn/a₩438.2b
A397030 AprilBioLtd
n/an/a₩359.4b

Price-To-Book vs Peers: Insufficient data to calculate A397030's Price-To-Book Ratio vs. peers for valuation analysis.


Price to Book Ratio vs Industry

How does A397030's PB Ratio compare vs other companies in the KR Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
A397030 is unprofitableIndustry Avg. 2.5xNo. of Companies11PB0246810+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: Insufficient data to calculate A397030's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is A397030's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A397030 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A397030's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies